Header Logo

Marta Batus

Concepts (147)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Sarcoma
9
2023
147
2.490
Why?
Lung Neoplasms
15
2024
552
1.900
Why?
Antineoplastic Agents
8
2016
198
1.790
Why?
Carcinoma, Non-Small-Cell Lung
14
2024
243
1.630
Why?
Soft Tissue Neoplasms
2
2022
54
0.890
Why?
Molecular Targeted Therapy
3
2013
33
0.860
Why?
Metastasectomy
1
2021
7
0.760
Why?
Antibodies, Monoclonal
4
2016
177
0.720
Why?
Bone Neoplasms
3
2022
130
0.720
Why?
Immunotherapy
3
2021
58
0.690
Why?
Antineoplastic Combined Chemotherapy Protocols
6
2019
245
0.640
Why?
Direct-to-Consumer Advertising
1
2016
1
0.520
Why?
Medical Oncology
1
2016
44
0.500
Why?
Chemoradiotherapy
4
2019
61
0.480
Why?
Retrospective Studies
16
2023
3538
0.450
Why?
Prognosis
9
2023
785
0.430
Why?
ErbB Receptors
4
2018
54
0.430
Why?
Melanoma
1
2013
60
0.400
Why?
Neoplasm Staging
11
2024
363
0.350
Why?
Humans
28
2024
27072
0.350
Why?
Survival Rate
5
2021
342
0.290
Why?
Mutation
3
2021
348
0.280
Why?
Carcinoma, Squamous Cell
4
2018
172
0.260
Why?
Neutrophils
2
2023
104
0.230
Why?
Female
17
2024
15212
0.230
Why?
Male
16
2024
14772
0.220
Why?
Body Composition
1
2024
68
0.220
Why?
Drug Resistance, Neoplasm
2
2018
69
0.220
Why?
Neoplasm Recurrence, Local
2
2016
206
0.220
Why?
Middle Aged
12
2024
8923
0.210
Why?
Receptor, IGF Type 1
2
2013
21
0.200
Why?
Quinazolines
2
2012
16
0.190
Why?
Sarcoma, Synovial
1
2022
12
0.190
Why?
High-Throughput Nucleotide Sequencing
1
2021
44
0.190
Why?
Pneumonectomy
1
2021
77
0.180
Why?
Antineoplastic Agents, Immunological
1
2021
15
0.180
Why?
Lung
1
2021
168
0.180
Why?
Adenocarcinoma
3
2018
137
0.170
Why?
Autoantibodies
1
2021
80
0.170
Why?
Treatment Outcome
8
2021
3485
0.160
Why?
Biomarkers, Tumor
1
2021
205
0.160
Why?
Erlotinib Hydrochloride
1
2018
11
0.150
Why?
Inflammation Mediators
1
2018
66
0.140
Why?
Aged
11
2024
8997
0.140
Why?
Survival Analysis
5
2021
257
0.140
Why?
Palliative Care
2
2015
110
0.140
Why?
Adult
7
2022
7831
0.130
Why?
Protein Kinase Inhibitors
2
2018
53
0.120
Why?
Gene Dosage
2
2012
19
0.120
Why?
Neoplasm Metastasis
2
2013
107
0.120
Why?
Biomarkers
1
2018
562
0.120
Why?
Radiotherapy, Conformal
1
2014
18
0.110
Why?
Cancer Vaccines
1
2013
7
0.110
Why?
Angiogenesis Inhibitors
1
2013
15
0.110
Why?
Neoplasms
1
2016
237
0.110
Why?
Forecasting
1
2013
91
0.100
Why?
Follow-Up Studies
5
2018
1792
0.100
Why?
Weight Gain
1
2012
64
0.100
Why?
PTEN Phosphohydrolase
1
2011
7
0.100
Why?
Fluorodeoxyglucose F18
2
2022
38
0.090
Why?
Positron Emission Tomography Computed Tomography
2
2022
36
0.090
Why?
Phosphatidylinositol 3-Kinases
1
2011
44
0.090
Why?
Adolescent
2
2016
2172
0.090
Why?
Child, Preschool
1
2013
641
0.090
Why?
Young Adult
2
2016
1994
0.090
Why?
Body Weight
2
2024
134
0.090
Why?
Gene Amplification
1
2010
21
0.090
Why?
Pyrimidines
1
2010
21
0.090
Why?
Xanthine Dehydrogenase
1
2010
6
0.090
Why?
Rectal Neoplasms
1
2010
14
0.090
Why?
Lymphocytes
2
2023
58
0.080
Why?
United States
1
2016
2035
0.080
Why?
Gastrointestinal Stromal Tumors
1
2010
30
0.080
Why?
Gene Expression Regulation, Neoplastic
1
2010
116
0.080
Why?
Piperazines
1
2010
85
0.080
Why?
Clinical Trials as Topic
1
2010
216
0.080
Why?
Child
1
2013
1295
0.080
Why?
Lymphohistiocytosis, Hemophagocytic
1
2008
9
0.080
Why?
Animals
2
2013
3642
0.070
Why?
Chromosomes, Human, Pair 10
1
2007
5
0.070
Why?
Chromosomes, Human, Pair 3
1
2007
7
0.070
Why?
Chromosomes, Human, Pair 1
1
2007
8
0.070
Why?
Receptor, ErbB-2
1
2007
51
0.070
Why?
Carcinoma, Large Cell
2
2018
12
0.060
Why?
Prospective Studies
2
2023
1778
0.060
Why?
Neoadjuvant Therapy
2
2019
65
0.060
Why?
Kaplan-Meier Estimate
2
2017
175
0.060
Why?
Aged, 80 and over
4
2018
4777
0.060
Why?
Etoposide
2
2015
27
0.050
Why?
Carboplatin
2
2015
26
0.050
Why?
Paclitaxel
2
2015
50
0.050
Why?
Lymphocyte Count
1
2023
17
0.050
Why?
Tumor Microenvironment
1
2023
20
0.050
Why?
Breast Neoplasms
1
2007
409
0.050
Why?
Margins of Excision
1
2022
32
0.050
Why?
Body Mass Index
1
2024
458
0.050
Why?
Time-to-Treatment
1
2022
34
0.050
Why?
Radiopharmaceuticals
1
2022
51
0.050
Why?
Positron-Emission Tomography
1
2022
87
0.050
Why?
B7-H1 Antigen
1
2021
8
0.050
Why?
Antigens, Neoplasm
1
2021
41
0.040
Why?
Programmed Cell Death 1 Receptor
1
2021
18
0.040
Why?
Observer Variation
1
2021
96
0.040
Why?
Cohort Studies
2
2015
1890
0.040
Why?
Patient Selection
1
2021
194
0.040
Why?
Mesna
1
2019
3
0.040
Why?
Ifosfamide
1
2019
14
0.040
Why?
Organ Sparing Treatments
1
2019
12
0.040
Why?
Leg
1
2019
50
0.040
Why?
Doxorubicin
1
2019
57
0.040
Why?
Tomography, X-Ray Computed
2
2014
683
0.040
Why?
Arm
1
2019
83
0.040
Why?
Time Factors
1
2022
1433
0.040
Why?
Proteomics
1
2018
89
0.030
Why?
Leukocyte Count
1
2017
61
0.030
Why?
Bevacizumab
1
2016
21
0.030
Why?
Taxoids
1
2016
10
0.030
Why?
Deoxycytidine
1
2016
23
0.030
Why?
Pemetrexed
1
2015
4
0.030
Why?
Radiation Pneumonitis
1
2015
4
0.030
Why?
Hemoptysis
1
2015
7
0.030
Why?
Esophagitis
1
2015
6
0.030
Why?
Cough
1
2015
8
0.030
Why?
Chest Pain
1
2015
19
0.030
Why?
Chemoradiotherapy, Adjuvant
1
2015
17
0.030
Why?
Radiation Injuries
1
2015
28
0.030
Why?
Dyspnea
1
2015
41
0.030
Why?
Disease-Free Survival
1
2015
174
0.030
Why?
Mobility Limitation
1
2015
94
0.030
Why?
Radiotherapy Dosage
1
2014
99
0.030
Why?
Radiotherapy Planning, Computer-Assisted
1
2014
51
0.030
Why?
Diet
1
2015
220
0.030
Why?
Class I Phosphatidylinositol 3-Kinases
1
2011
9
0.020
Why?
Immunohistochemistry
1
2012
366
0.020
Why?
Activities of Daily Living
1
2015
595
0.020
Why?
Imatinib Mesylate
1
2010
8
0.020
Why?
Benzamides
1
2010
15
0.020
Why?
Colectomy
1
2010
20
0.020
Why?
Combined Modality Therapy
1
2011
300
0.020
Why?
Quality of Life
1
2015
629
0.020
Why?
Biopsy
1
2010
201
0.020
Why?
Signal Transduction
1
2012
443
0.020
Why?
Smoking
1
2010
176
0.020
Why?
Risk Assessment
1
2011
624
0.020
Why?
Fatal Outcome
1
2008
54
0.020
Why?
Trastuzumab
1
2007
26
0.020
Why?
Antibodies, Monoclonal, Humanized
1
2007
85
0.020
Why?
Batus's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (147)
Explore
_
Co-Authors (26)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_